Expression and clinical value of serum LncRNA LINC00707 and miR-382-5p in patients with pulmonary tuberculosis

doi:10.19982/j.issn.1000-6621.20250383

Abstract

Abstract:

Objective：To investigate the expression of long non-coding RNA （LncRNA） LINC00707 and micro RNA-382-5p （miR-382-5p） in the serum of pulmonary tuberculosis patients and their clinical diagnostic values for pulmonary tuberculosis. Methods：From July 2021 to July 2023，pulmonary tuberculosis patients admitted to Shaanxi Provincial Tuberculosis Prevention and Treatment Institute were regarded as tuberculosis group，including 38 cases of active pulmonary tuberculosis and 27 cases of inactive pulmonary tuberculosis. And another 68 non-tuberculosis patients admitted to the respiratory outpatient department during the same period were selected as non-tuberculosis group，and 68 healthy individuals who underwent physical examinations were regarded as control group；the expression levels of serum LncRNA LINC00707 and miR-382-5p were compared among the four groups；the relationship between the expression levels of serum LncRNA LINC00707 and miR-382-5p in patients with pulmonary tuberculosis and their clinical pathological characteristics was analyzed；Bioinformatics website was used to predict the targeting relationship between miR-382-5p and LncRNA LINC00707；Multivariable logistic regression was performed to analyze factors affecting pulmonary tuberculosis’s occurrence；Receiver operating characteristic （ROC） curve was applied to analyze the diagnostic efficacy of serum LncRNA LINC00707 and miR-382-5p levels for pulmonary tuberculosis. Results：Analyzing the expression levels of serum TNF-α （（3.31±1.01），（20.15±5.47），（32.46±7.05），（42.89±8.96） ng/L），IL-1β （（13.62±3.87），（47.96±6.81），（65.86±9.14），（83.17±10.59） ng/L），LncRNA LINC00707 （（1.06±0.17），（1.21±0.23），（1.35±0.19），（1.63±0.32）） and miR-382-5p （（0.97±0.15），（0.91±0.11），（0.83±0.12），（0.74±0.09）） in the serum of the reference group，non-tuberculosis group，inactive tuberculosis group，and active tuberculosis group，it was found that TNF-α，IL-1β，LncRNA LINC00707 were highest in the active tuberculosis group and lowest in the control group，while miR-382-5p expression level was highest in the control group and lowest in the active tuberculosis group. The differences among the groups were all statistically significant （F=445.800，847.483，53.455，31.014，P<0.001）. Logistic regression analysis showed that LINC00707 （OR （95%CI）=1.735 （1.350-2.230）），miR-382-5p （OR （95%CI）=0.816 （0.735-0.905）），IL-1β （OR （95%CI）=1.413 （1.087-1.837）），TNF-α （OR （95%CI）=1.259 （1.001-1.584）） were influencing factors of pulmonary tuberculosis. ROC curve showed that the areas under the curve （AUCs） of serum LncRNA LINC00707，miR-382-5p levels，and their combined diagnosis for pulmonary tuberculosis were 0.805，0.758，and 0.903，respectively. The clinical efficacy of combined diagnosis was superior to that of solely using serum LncRNA LINC00707 and miR-382-5p （Z=2.070，P=0.038；Z=2.826，P=0.005）. Conclusion：The expression of serum LncRNA LINC00707 in patients with pulmonary tuberculosis is obviously increased，while the expression of miR-382-5p is obviously reduced. Combination of these two has a higher clinical efficacy in diagnosing pulmonary tuberculosis.

Key words: Tuberculosis, pulmonary, Serum, RNA, Diagnosis

CLC Number:

R521

Zhong Guowei, Zhang Shaoyi, Fan Huiling. Expression and clinical value of serum LncRNA LINC00707 and miR-382-5p in patients with pulmonary tuberculosis[J]. Chinese Journal of Antituberculosis, 2026, 48(4): 495-503. doi: 10.19982/j.issn.1000-6621.20250383

Figures/Tables 11

References 28

[1]	陈伟, 孙慧娟, 赵雁林. 新时期我国结核病防治服务体系建设及展望. 结核与肺部疾病杂志, 2024, 5 (2): 95-100. doi:10.19983/j.issn.2096-8493.2024025.
[2]	杨艳, 董文, 陈建军, 等. 2014—2023年湖北省十堰市竹溪县肺结核流行特征分析. 结核与肺部疾病杂志, 2025, 6(1):40-45. doi:10.19983/j.issn.2096-8493.2024155.
[3]	李玲, 王涛, 梁建琴, 等. 基于转录组表达数据筛选肺结核患者的生物标志物及疾病进展预测. 中华结核和呼吸杂志, 2025, 48(7): 649-655. doi:10.3760/cma.j.cn112147-20250219-00092.
[4]	Luo Y, Wang Q, Teng L, et al. LncRNA DANCR promotes proliferation and metastasis in pancreatic cancer by regulating miRNA-33b. FEBS Open Bio, 2020, 10(1):18-27. doi:10.1002/2211-5463.12732. pmid: 31515968
[5]	Qian M, Shi Y, Lu W. LINC 00707 knockdown inhibits IL-1β-induced apoptosis and extracellular matrix degradation of osteoarthritis chondrocytes by the miR-330-5p/FSHR axis. Immunopharmacol Immunotoxicol, 2022, 44(5):671-681. doi:10.1080/08923973.2022.2076241.
[6]	Chen L, Chen Y, Huang J, et al. LncRNA LINC00707 serves as a sponge of miR-382-5p to alleviate lipopolysaccharide (LPS)-induced WI-38 cell injury through upregulating NKAP in infantile pneumonia. Autoimmunity, 2022, 55(5): 328-338. doi:10.1080/08916934.2022.2062594.
[7]	Xiao Y, Li C, Wang H, et al. LINC00265 targets miR-382-5p to regulate SAT1, VAV3 and angiogenesis in osteosarcoma. Aging (Albany NY), 2020, 12(20): 20212-20225. doi:10.18632/aging.103762.
[8]	Lv Y, Li Y, Wang J, et al. MiR-382-5p suppresses M1 macrophage polarization and inflammatory response in response to bronchopulmonary dysplasia through targeting CDK8: Involving inhibition of STAT1 pathway. Genes Cells, 2021, 26(10): 772-781. doi:10.1111/gtc.12883.
[9]	中华医学会结核病学分会, 结核病病理学诊断专家共识编写组. 中国结核病病理学诊断专家共识. 中华结核和呼吸杂志, 2017, 40(6): 419-425. doi:10.3760/cma.j.issn.1001-0939.2017.06.005.
[10]	中华人民共和国国家卫生和计划生育委员会. WS 288—2017肺结核诊断. 结核与肺部疾病杂志, 2024, 5(4): 376-378. doi:10.19983/j.issn.2096-8493.2024022.
[11]	屈燕, 李涛, 马文斌, 等. 世界卫生组织《2025年全球结核病报告》解读. 结核与肺部疾病杂志, 2025, 6 (6): 613-623. doi:10.19983/j.issn.2096-8493.20250178.
[12]	马晓格, 张立杰, 高汉青, 等. 基于多因素logistic回归模型和决策树模型的肺结核患者就诊延迟及确诊延迟影响因素分析. 中华流行病学杂志, 2024, 45(5): 721-729. doi:10.3760/cma.j.cn112338-20240224-00080.
[13]	Long R, Lau A, Barrie J, et al. Limitations of Chest Radiography in Diagnosing Subclinical Pulmonary Tuberculosis in Canada. Mayo Clin Proc Innov Qual Outcomes, 2023, 7(3):165-170. doi:10.1016/j.mayocpiqo.2023.03.003. pmid: 37168770
[14]	赵勇, 梁丽丽, 江南. LncRNA GAS5靶向调控miR-144-3p对结核分枝杆菌感染的巨噬细胞凋亡和炎性反应的影响. 中国防痨杂志, 2023, 45(8): 744-751. doi:10.19982/j.issn.1000-6621.20230105.
[15]	Tan YT, Lin JF, Li T, et al. LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer. Cancer Commun (Lond), 2021, 41(2): 109-120. doi:10.1002/cac2.12108.
[16]	Yao Q, Li Z, Chen D. Review of LINC00707: A Novel LncRNA and Promising Biomarker for Human Diseases. Front Cell Dev Biol, 2022, 10: 813963. doi:10.3389/fcell.2022.813963.
[17]	Zou X, Gao C, Shang R, et al. Knockdown of lncRNA LINC00707 alleviates LPS-induced injury in MRC-5 cells by acting as a ceRNA of miR-223-5p. Biosci Biotechnol Biochem, 2021, 85(2): 315-323. doi:10.1093/bbb/zbaa069.
[18]	Ye H, Chen Y, Xia H, et al. Inhibition of LINC00707/miR-223-3p/FKBP5 axis has a protective effect on diabetic kidney disease. J Diabetes Investig, 2025, 16(6):1034-1044. doi:10.1111/jdi.70025.
[19]	Ashmwe M, Posa K, Rührnößl A, et al. Effects of Extracorporeal Shockwave Therapy on Functional Recovery and Circulating miR-375 and miR-382-5p after Subacute and Chronic Spinal Cord Contusion Injury in Rats. Biomedicines, 2022, 10(7): 1630. doi:10.3390/biomedicines10071630.
[20]	Zhang X, Zhang Y, Meng Q, et al. MicroRNA-382-5p is involved in pulmonary inflammation induced by fine particulate matter exposure. Environ Pollut, 2020, 262: 114278. doi:10.1016/j.envpol.2020.114278.
[21]	Murer A, Rühl J, Zbinden A, et al. MicroRNAs of Epstein-Barr Virus Attenuate T-Cell-Mediated Immune Control In Vivo. mBio, 2019, 10(1): e01941-18. doi:10.1128/mBio.01941-18.
[22]	毕婧, 黄波. 外周血miR-92a和miR-342在急性肺损伤的诊断及预后中的临床价值. 实用医学杂志, 2023, 39(3): 360-363, 368. doi:10.3969/j.issn.1006-5725.2023.03.017.
[23]	孙程圆, 邵将, 刘超, 等. miRNA在垂体腺瘤中作用机制的研究进展. 癌症进展, 2023, 21(1):19-25. doi:10.11877/j.issn.1672-1535.2022.21.01.04.
[24]	黄洪阳, 蔡丽龙, 陈万灵. miR-24在血液系统恶性肿瘤中的研究进展. 重庆医学, 2024, 53(S1): 197-199.
[25]	Chang Q, Li C, Hu J, et al. Protective effects of hsa_circ_0072568 on interleukin-1β-stimulated human chondrocytes are mediated via the miR-382-5p/TOP1 axis. Exp Ther Med, 2023, 26(2): 383. doi:10.3892/etm.2023.12082.
[26]	周利君, 郭红荣, 王红娟, 等. 非小细胞肺癌组织中LINC00707、miR-382-5p表达及其与患者预后的关系. 东南大学学报(医学版), 2023, 42(5): 724-729. doi:10.3969/j.issn.1671-6264.2023.05.011.
[27]	李红亚, 吕园园, 张丛敏, 等. miR-382-5p、PCT、SAA、CRP与早产儿肺部疾病相关性研究. 中国妇幼健康研究, 2023, 34(9):62-67. doi:10.3969/j.issn.1673-5293.2023.09.012.
[28]	朱大映, 秦峰. 血清微小RNA-582-5p和微小RNA-215-5p在肺结核患者中的表达及临床意义. 传染病信息, 2024, 37(5):424-428. doi:10.3969/j.issn.1007-8134.2024.05.008.

基因	上游引物（5'-3'）	下游引物（5'-3'）
LncRNA LINC00707	CCAACAGGGTATCAGAATTCTC	TGCTGACAATAGCCATTAGG
GAPDH	GCACCGTCAAGGCTGAGAAC	TGGTGAAGACGCCAGTGGA
miR-382-5p	CTCGCTTCGGCAGCACA	TATGGTTGTAGAGGACTCCTTGAC
U6	AACGCTTCACGAATTTGCGT	CTCGCTTCGGCAGCACA

指标	活动性肺结核组（38例）	非活动性肺结核组（27例）	非肺结核组（68例）	对照组（68名）	统计检验值	P值
年龄（岁，$\overline{x}$±s）	45.61±10.69	43.25±9.85	43.49±10.64	43.15±11.03	F=0.488	0.691
性别[例（构成比，%）]					χ²=1.562	0.668
男性	19（50.0）	17（63.0）	39（57.4）	35（51.5）
女性	19（50.0）	10（37.0）	29（42.6）	33（48.5）
病程（月，$\overline{x}$±s）	6.34±1.25	6.19±1.09	6.05±1.27	-	F=0.686	0.505
吸烟史[例（构成比，%）]					χ²=5.457	0.142
有	25（65.8）	21（77.8）	38（55.9）	37（54.4）
无	13（34.2）	6（22.2）	30（44.1）	31（45.6）
TNF-α（ng/L，$\overline{x}$±s）	42.89±8.96^abc	32.46±7.05^ab	20.15±5.47^a	3.31±1.01	F=445.800	<0.001
IL-1β（ng/L，$\overline{x}$±s）	83.17±10.59^abc	65.86±9.14^ab	47.96±6.81^a	13.62±3.87	F=847.483	<0.001

指标	活动性肺结核组（38例）	非活动性肺结核组（27例）	非肺结核组（68例）				对照组（68名）	F值	P值
指标	活动性肺结核组（38例）	非活动性肺结核组（27例）	呼吸道感染（27例）	慢性阻塞性肺疾病（19例）	哮喘（22例）	均值	对照组（68名）	F值	P值
LncRNA LINC00707	1.63±0.32^abc	1.35±0.19^ab	1.18±0.15	1.21±0.18	1.24±0.19	1.21±0.23^a	1.06±0.17	53.455	<0.001
miR-382-5p	0.74±0.09^abc	0.83±0.12^ab	0.88±0.12	0.90±0.14	0.95±0.18	0.91±0.11^a	0.97±0.15	31.014	<0.001

指标	例数	LncRNA LINC00707	t值	P值	miR-382-5p	t值	P值
年龄组（岁）			0.260	0.796		0.666	0.508
>60	31	1.53±0.48			0.77±0.11
≤60	34	1.50±0.45			0.79±0.13
性别			0.518	0.606		1.928	0.058
男性	36	1.54±0.49			0.75±0.10
女性	29	1.48±0.43			0.81±0.15
吸烟史			2.007	0.049		4.487	<0.001
有	49	1.58±0.51			0.74±0.10
无	16	1.31±0.29			0.90±0.18
病程			1.690	0.096		1.868	0.066
≤6个月	32	1.43±0.35			0.82±0.17
>6个月	33	1.59±0.41			0.75±0.13
结核空洞			2.065	0.043		3.983	<0.001
有	26	1.65±0.50			0.71±0.10
无	39	1.41±0.43			0.83±0.13
病灶范围			2.253	0.028		2.949	0.004
1~3个肺野	37	1.40±0.42			0.82±0.13
4~6个肺野	28	1.66±0.51			0.73±0.11

因素	β值	s${}_{\overline{x}}$值	Wald χ²值	P值	OR值	95%CI值
LncRNA LINC00707	0.551	0.128	18.531	<0.001	1.735	1.350~2.230
miR-382-5p	―0.203	0.053	14.720	<0.001	0.816	0.735~0.905
IL-1β	0.346	0.134	6.656	0.010	1.413	1.087~1.837
TNF-α	0.230	0.117	3.875	0.049	1.259	1.001~1.584